Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1984 Oct;28(5):563-6.
doi: 10.1111/j.1399-6576.1984.tb02120.x.

Cardiovascular response to endotracheal intubation during four anesthetic techniques

Comparative Study

Cardiovascular response to endotracheal intubation during four anesthetic techniques

R F Bedford et al. Acta Anaesthesiol Scand. 1984 Oct.

Abstract

In order to investigate the impact of four different anesthetic regimens on the cardiovascular response to endotracheal intubation, 24 patients were anesthetized to approximately the same depth of anesthesia (MAC-fraction) using one of four supplements to N2O-O2 (60:40) anesthesia: Group 1 = morphine 0.5 mg/kg i.v., Group 2 = Innovar 0.1 ml/kg i.v., Group 3 = halothane, 0.4% end-tidal, Group 4 = enflurane 0.7% end-tidal. Cardiovascular variables were recorded from radial arterial and thermistor-tipped pulmonary artery catheters and were determined at the following times: (1) while the patients were awake prior to induction of anesthesia; (2) after a stable level of anesthesia had been induced; and (3) within the first minute after endotracheal intubation. Only the groups receiving morphine and halothane sustained significant increases in heart rate, rate pressure product and pulmonary capillary wedge pressure after intubation. It is concluded that N2O-O2 anesthesia supplemented with either morphine or halothane at the 1 MAC dose level does not adequately prevent cardiovascular response after endotracheal intubation, and that these techniques require additional anesthetic depth or other adjuvant drugs in order to prevent cardiovascular complications.

PubMed Disclaimer

Publication types

LinkOut - more resources